<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01855607</url>
  </required_header>
  <id_info>
    <org_study_id>AAAL2664</org_study_id>
    <nct_id>NCT01855607</nct_id>
  </id_info>
  <brief_title>Topical Menthol for the Treatment of Chemotherapy Induced Peripheral Neuropathy</brief_title>
  <official_title>Topical Menthol for CIPN: a Randomized, Placebo Controlled Phase II Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Columbia University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Columbia University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To assess whether six week treatment with twice a day topical Menthol application will
      decrease persistent neuropathic pain from chemotherapy among breast and colorectal cancer
      patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To assess whether six week treatment with BID topical Menthol application will decrease
      persistent neuropathic pain as measured by the change in Brief Pain Inventory-Short Form
      (BPI-SF worst pain score), following neoadjuvant/adjuvant chemotherapy with taxanes or
      oxaliplatin-based regimens among breast and colorectal cancer patients.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>August 2013</start_date>
  <completion_date type="Anticipated">July 2016</completion_date>
  <primary_completion_date type="Anticipated">July 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Prevalence of decrease in neuropathic pain</measure>
    <time_frame>6 weeks</time_frame>
    <description>measured by BPI-SF scale</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in sensory and motor function</measure>
    <time_frame>6 weeks</time_frame>
    <description>grooved pegboard and vibrometer</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Breast Cancer</condition>
  <condition>Colon Cancer</condition>
  <arm_group>
    <arm_group_label>topical menthol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>topical menthol cream to hands and feet</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo cream</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>topical cream without menthol</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>topical menthol</intervention_name>
    <description>7.5% Methylsalicylate / 2% Menthol Lotion</description>
    <arm_group_label>topical menthol</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>placebo cream</intervention_name>
    <description>The control (placebo) product has same amount of Methylsalicylate (7.5%) and no menthol.</description>
    <arm_group_label>placebo cream</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age&gt;21 years

          2. History of stage I-III breast or colorectal cancer

          3. Patient has to have completed adjuvant or neo-adjuvant Taxane based breast cancer
             therapy or Oxaliplatin based colon cancer chemotherapy between one and 24 months prior
             to registration

          4. Signed informed consent

          5. Concomitant biologic, hormonal or radiation therapy are acceptable.

          6. Narcotics, antidepressants or other medications for the treatment of CIPN are
             permitted, if patient on a stable dose for at least one month prior to enrollment.

          7. Pain as defined by BPI worst pain greater than or equal to a 5 out of 10.

          8. CIPN as defined by experiencing neuropathy (numbness, tingling, thermal hyperalgesia
             or cold allodynia) in the hands and feet frequently or most of the time in the past
             seven days.

        Exclusion Criteria:

          1. Previous treatment with topical menthol (menthol/methylsalicylate products like
             BenGay, Aspercreme, or Icy Hot) of any concentration within the previous 3 months

          2. Known diabetic neuropathy

          3. Severe concomitant illnesses

          4. Known allergy or preexisting skin disease which prohibits use of menthol

          5. Any topical treatment for neuropathy or other serious skin condition on the hands or
             feet.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dawn Hershman, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Columbia University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Dawn L Hershman, MD</last_name>
    <phone>212 305-1945</phone>
    <email>dlh23@columbia.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Dan Otap</last_name>
    <email>do2267@cumc.columbia.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Herbert Irving Comprehensive Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Katherine Crew</last_name>
      <email>dlh23@columbia.edu</email>
    </contact>
    <investigator>
      <last_name>Katherine Crew, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Dawn Hershman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 14, 2013</study_first_submitted>
  <study_first_submitted_qc>May 14, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 16, 2013</study_first_posted>
  <last_update_submitted>June 30, 2015</last_update_submitted>
  <last_update_submitted_qc>June 30, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 2, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>chemotherapy induced neuropathy</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Menthol</mesh_term>
    <mesh_term>Methyl salicylate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

